| 8.08 -0.69 (-7.87%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 14.68  |
1-year : | 17.92 |
| Resists | First : | 12.56 |
Second : | 15.35 |
| Pivot price | 9.76 |
|||
| Supports | First : | 8.06 |
Second : | 6.71 |
| MAs | MA(5) : | 8.85 |
MA(20) : | 10.5 |
| MA(100) : | 10.94  |
MA(250) : | 8.54 |
|
| MACD | MACD : | -1.2 |
Signal : | -1 |
| %K %D | K(14,3) : | 1.4 |
D(3) : | 3.4 |
| RSI | RSI(14): 20.1 |
|||
| 52-week | High : | 16.64 | Low : | 4.9 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ORIC ] has closed above bottom band by 0.6%. Bollinger Bands are 3.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 8.83 - 8.87 | 8.87 - 8.91 |
| Low: | 7.93 - 7.99 | 7.99 - 8.05 |
| Close: | 7.98 - 8.08 | 8.08 - 8.16 |
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Tue, 23 Apr 2024
(ORIC) Trading Report - Stock Traders Daily
Wed, 10 Apr 2024
Oric Pharmaceuticals reports on highly potent, selective and orally bioavailable PLK4 inhibitor - BioWorld Online
Fri, 05 Apr 2024
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Thu, 04 Apr 2024
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences - Yahoo Finance
Fri, 29 Mar 2024
ORIC Pharmaceuticals Stock: Rally Seems Overdone - Seeking Alpha
Tue, 12 Mar 2024
These Analysts Revise Their Forecasts On ORIC Pharmaceuticals After Q4 Results - Markets Insider
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 67 (M) |
| Shares Float | 37 (M) |
| Held by Insiders | 9.5 (%) |
| Held by Institutions | 88.4 (%) |
| Shares Short | 8,140 (K) |
| Shares Short P.Month | 6,490 (K) |
| EPS | -1.97 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.07 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -27.8 % |
| Return on Equity (ttm) | -45.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.63 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -86 (M) |
| Levered Free Cash Flow | -49 (M) |
| PE Ratio | -4.13 |
| PEG Ratio | 0 |
| Price to Book value | 1.98 |
| Price to Sales | 0 |
| Price to Cash Flow | -6.36 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|